Drug
Adagrasib
Adagrasib: highest development phase Phase 3, developed by Mirati Therapeutics. 9 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Mirati Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Adagrasib NCT06875310 | Phase 3 | Carcinoma, Non-Small-Cell Lung |
| Adagrasib NCT04613596 | Phase 2/3 | Advanced Non-Small Cell Lung Cancer |
| Adagrasib NCT07415031 | Phase 2 | Solid Tumors |
| Adagrasib NCT05853575 | Phase 2 | Advanced Cancer |
| Adagrasib NCT05472623 | Phase 2 | Resectable Non-Small Cell Lung Cancer |
| Adagrasib NCT07723118 | Phase 1 | Healthy Participants |
| Adagrasib NCT05924152 | Phase 1 | Healthy Adults |
| Adagrasib NCT06130254 | Phase 1 | Advanced Solid Tumor |
| Adagrasib NCT05840510 | Phase 1 | Solid Tumor, Adult |
Latest
Follow Adagrasib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.